Murat Gökhan Yerlikaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Murat Gökhan Yerlikaya has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Özderya
Department of Cardiology, Trabzon Kanuni Training and Research Hospital, Trabzon, Türkiye
7 shared publications - Ali Riza Akyuz
Department of Cardiology, University of Health Sciences, Trabzon Ahi Evren Thoracic and Cardiovascular Surgery Training and Research Hospital, Trabzon, Türkiye
7 shared publications - Levent Korkmaz
Department of Cardiology, Ahi Evren Cardiovascular and Thoracic Surgery Training and Research Hospital, Trabzon, Turkey
4 shared publications - Ali Hakan Konuş
Department of Cardiology, Bingol State Hospital
3 shared publications - Fatih Gülçebi
Department of Cardiology, Trabzon Kanuni Training and Research Hospital, 61250 Trabzon, Turkey
3 shared publications - Selim Kul
Department of Cardiology
3 shared publications
Latest Publications
- 6 November 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Sequential Coronary Obstruction After Native TAVI: Immediate Acute Occlusion and Very Late Stent Compression by Aortic Wall Hematoma
Coronary obstruction is a rare but catastrophic complication of transcatheter aortic valve implantation (TAVI) associated with high mortality. While acute and delayed presentations have distinct pathophysiological mechanisms, their occurrence in the same patient is exceedingly rare. We present a unique case of a 91‐year‐old female who developed acute left main coronary artery (LMCA) obstruction immediately following native TAVI using a balloon‐expandable valve, which was successfully treated with bail‐out percutaneous coronary intervention (PCI). Three months later (> 60 days, classified as “Very Late” coronary obstruction), she presented with severe angina and heart failure. Intravascular ultrasound (IVUS) revealed extrinsic compression of the previously implanted coronary stent caused by a localized aortic wall hematoma. A repeat PCI with a stent‐in‐stent technique restored coronary flow, leading to complete clinical recovery. This case expands the known mechanical spectrum of very late coronary obstruction according to recent classification frameworks and highlights the vital role of intravascular imaging and multimodality assessment in diagnosis and management.
- 6 November 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Sequential Coronary Obstruction After Native TAVI: Immediate Acute Occlusion and Very Late Stent Compression by Aortic Wall Hematoma
Coronary obstruction is a rare but catastrophic complication of transcatheter aortic valve implantation (TAVI) associated with high mortality. While acute and delayed presentations have distinct pathophysiological mechanisms, their occurrence in the same patient is exceedingly rare. We present a unique case of a 91‐year‐old female who developed acute left main coronary artery (LMCA) obstruction immediately following native TAVI using a balloon‐expandable valve, which was successfully treated with bail‐out percutaneous coronary intervention (PCI). Three months later (> 60 days, classified as “Very Late” coronary obstruction), she presented with severe angina and heart failure. Intravascular ultrasound (IVUS) revealed extrinsic compression of the previously implanted coronary stent caused by a localized aortic wall hematoma. A repeat PCI with a stent‐in‐stent technique restored coronary flow, leading to complete clinical recovery. This case expands the known mechanical spectrum of very late coronary obstruction according to recent classification frameworks and highlights the vital role of intravascular imaging and multimodality assessment in diagnosis and management.
- Open Access
Comparison of Clinical Outcomes of Myval vs. Acurate Neo Valves in TAVR: A Single-Center Experience
Background and Objectives: Transcatheter aortic valve replacement (TAVR) has become an established treatment for severe symptomatic aortic stenosis, and continuous technological advances have led to the development of different transcatheter heart valve (THV) systems. This study aimed to compare the short- and mid-term clinical outcomes of the balloon-expandable Myval (Meril Life Sciences, India) and the self-expanding Acurate Neo (Boston Scientific, MA, USA) transcatheter heart valves during a mean follow-up of 18 months. Materials and Methods: This retrospective single-center study included consecutive patients who underwent transfemoral TAVR with either the Myval or Acurate Neo valve between January 2020 and September 2022. Demographic, clinical, laboratory, electrocardiographic, echocardiographic, procedural, and follow-up data were collected and compared. Clinical outcomes were evaluated according to the Valve Academic Research Consortium-3 (VARC-3) criteria. Results: A total of 147 patients were included (Myval, n = 116; Acurate Neo, n = 31). Predilatation was performed in all patients in the Acurate Neo group but in only 22 (18.9%) patients in the Myval group (p < 0.001). In-hospital mild paravalvular leak (PVL) was more frequent in the Acurate Neo group (38.7% vs. 20.6%; p = 0.038), whereas moderate or greater PVL did not differ between the groups. During a mean follow-up of 18 months (range, 10–32 months), mild PVL remained significantly more frequent in the Acurate Neo group (p = 0.028). No significant differences were observed between the two valve systems regarding mortality, permanent pacemaker implantation, or other major VARC-3 clinical outcomes. Conclusions: The Myval and Acurate Neo transcatheter heart valves demonstrated comparable short- and mid-term clinical outcomes in patients undergoing TAVR. Although mild PVL was more frequent with the Acurate Neo valve, mortality, permanent pacemaker implantation, and moderate or greater PVL were similar between the two valve systems, supporting the safety and effectiveness of both prostheses in the treatment of severe symptomatic aortic stenosis.
Open AccessComparison of Clinical Outcomes of Myval vs. Acurate Neo Valves in TAVR: A Single-Center Experience
Background and Objectives: Transcatheter aortic valve replacement (TAVR) has become an established treatment for severe symptomatic aortic stenosis, and continuous technological advances have led to the development of different transcatheter heart valve (THV) systems. This study aimed to compare the short- and mid-term clinical outcomes of the balloon-expandable Myval (Meril Life Sciences, India) and the self-expanding Acurate Neo (Boston Scientific, MA, USA) transcatheter heart valves during a mean follow-up of 18 months. Materials and Methods: This retrospective single-center study included consecutive patients who underwent transfemoral TAVR with either the Myval or Acurate Neo valve between January 2020 and September 2022. Demographic, clinical, laboratory, electrocardiographic, echocardiographic, procedural, and follow-up data were collected and compared. Clinical outcomes were evaluated according to the Valve Academic Research Consortium-3 (VARC-3) criteria. Results: A total of 147 patients were included (Myval, n = 116; Acurate Neo, n = 31). Predilatation was performed in all patients in the Acurate Neo group but in only 22 (18.9%) patients in the Myval group (p < 0.001). In-hospital mild paravalvular leak (PVL) was more frequent in the Acurate Neo group (38.7% vs. 20.6%; p = 0.038), whereas moderate or greater PVL did not differ between the groups. During a mean follow-up of 18 months (range, 10–32 months), mild PVL remained significantly more frequent in the Acurate Neo group (p = 0.028). No significant differences were observed between the two valve systems regarding mortality, permanent pacemaker implantation, or other major VARC-3 clinical outcomes. Conclusions: The Myval and Acurate Neo transcatheter heart valves demonstrated comparable short- and mid-term clinical outcomes in patients undergoing TAVR. Although mild PVL was more frequent with the Acurate Neo valve, mortality, permanent pacemaker implantation, and moderate or greater PVL were similar between the two valve systems, supporting the safety and effectiveness of both prostheses in the treatment of severe symptomatic aortic stenosis.
- Open Access
- 6 May 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25
Efficacy and safety of combination therapy with statin and ezetimibe in patients failing to achieve target LDL levels at cardiology outpatient clinics in Turkey (COM-TR-OLDL): a real-world observational study
Background: Achieving target low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD) frequently requires combination lipid-lowering therapy. Single-pill combination (SPC) regimens may improve adherence compared with free-dose combinations (FDC) in real-world clinical practice. Methods: This retrospective observational study included 450 ASCVD patients with baseline LDL-C levels of 70–189 mg/dL who were followed in cardiology outpatient clinics between January 2023 and December 2024. Patients received atorvastatin–ezetimibe either as a single-pill combination (SPC, n = 392) or as a free-dose combination (FDC, n = 58). Primary endpoints were LDL-C reduction and treatment adherence (≥ 80% of prescribed doses). Secondary endpoints included LDL-C target attainment and adverse events. Non-parametric tests and chi-square/Fisher’s exact tests were used for statistical analysis. Results: At 1 month, LDL-C levels were significantly lower in the SPC group compared with the FDC group (90.6 vs. 119 mg/dL; p = 0.005), and adherence was higher (89.8% vs. 70.7%; p < 0.001). At 4 months, LDL-C levels were comparable between groups, while continuous adherence remained significantly higher in the SPC group (86% vs. 69%; p = 0.001). A higher proportion of SPC-treated patients achieved LDL-C < 100 mg/dL at 1 month (81.9% vs. 67.2%; p = 0.009). Conclusions: In this real-world ASCVD cohort, SPC therapy with atorvastatin and ezetimibe was associated with superior adherence and comparable lipid-lowering efficacy despite lower statin doses. Fixed-dose combination strategies may represent an effective approach to optimize adherence and cardiovascular risk management.
- 6 May 2026
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 25
Open AccessEfficacy and safety of combination therapy with statin and ezetimibe in patients failing to achieve target LDL levels at cardiology outpatient clinics in Turkey (COM-TR-OLDL): a real-world observational study
Background: Achieving target low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease (ASCVD) frequently requires combination lipid-lowering therapy. Single-pill combination (SPC) regimens may improve adherence compared with free-dose combinations (FDC) in real-world clinical practice. Methods: This retrospective observational study included 450 ASCVD patients with baseline LDL-C levels of 70–189 mg/dL who were followed in cardiology outpatient clinics between January 2023 and December 2024. Patients received atorvastatin–ezetimibe either as a single-pill combination (SPC, n = 392) or as a free-dose combination (FDC, n = 58). Primary endpoints were LDL-C reduction and treatment adherence (≥ 80% of prescribed doses). Secondary endpoints included LDL-C target attainment and adverse events. Non-parametric tests and chi-square/Fisher’s exact tests were used for statistical analysis. Results: At 1 month, LDL-C levels were significantly lower in the SPC group compared with the FDC group (90.6 vs. 119 mg/dL; p = 0.005), and adherence was higher (89.8% vs. 70.7%; p < 0.001). At 4 months, LDL-C levels were comparable between groups, while continuous adherence remained significantly higher in the SPC group (86% vs. 69%; p = 0.001). A higher proportion of SPC-treated patients achieved LDL-C < 100 mg/dL at 1 month (81.9% vs. 67.2%; p = 0.009). Conclusions: In this real-world ASCVD cohort, SPC therapy with atorvastatin and ezetimibe was associated with superior adherence and comparable lipid-lowering efficacy despite lower statin doses. Fixed-dose combination strategies may represent an effective approach to optimize adherence and cardiovascular risk management.
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (3) , e016071
Long-Term Prognosis of Acute Myocardial Infarction Caused by Isolated Diffuse Coronary Artery Ectasia
BACKGROUND: Isolated coronary artery ectasia (CAE) is a less common form of CAE. The clinical significance of isolated CAE has not been elucidated yet. We aimed to compare the patients with myocardial infarction (MI) due to isolated CAE with the patients without CAE. METHODS: We retrospectively included patients who underwent coronary angiography with a diagnosis of first MI caused by isolated CAE. We excluded patients with >20% stenosis in any vessel other than the lesion responsible for the MI. A second group of patients with MI without CAE was selected as the control group. The primary outcome was the composite of all-cause death and nonfatal recurrent MI occurring after index hospitalization. RESULTS: A total of 404 patients were included. Overall, 63.9% of MIs were ST-elevation MI. Almost all patients in the isolated CAE group had multivessel diffuse ectasia, with 71.3% classified as Markis I, and 26.7% as Markis II. Death or MI recurrence occurred in 54 (26.7%) patients in the isolated CAE group and 33 (16.3%) patients in the control group ( P =0.011). Death occurred in 8 (4.0%) patients in the isolated CAE group versus 6 (3.0%) patients in the control group; recurrent MI in 46 (22.8%) versus 27 (13.4%) patients, respectively. Stent thrombosis was more common in the CAE group compared with the control group (8.9% versus 1.5%; P P =0.017), and recurrent MI (hazard ratio, 2.07 [95% CI, 1.08–3.96]; P =0.029). CONCLUSIONS: The patients with MI due to isolated CAE had a higher risk of recurrent MI and stent thrombosis compared with the patients without CAE. In this study, the rate of recurrent MI from the index infarct artery was also higher in the patients with CAE.
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (3) , e016071
Long-Term Prognosis of Acute Myocardial Infarction Caused by Isolated Diffuse Coronary Artery Ectasia
BACKGROUND: Isolated coronary artery ectasia (CAE) is a less common form of CAE. The clinical significance of isolated CAE has not been elucidated yet. We aimed to compare the patients with myocardial infarction (MI) due to isolated CAE with the patients without CAE. METHODS: We retrospectively included patients who underwent coronary angiography with a diagnosis of first MI caused by isolated CAE. We excluded patients with >20% stenosis in any vessel other than the lesion responsible for the MI. A second group of patients with MI without CAE was selected as the control group. The primary outcome was the composite of all-cause death and nonfatal recurrent MI occurring after index hospitalization. RESULTS: A total of 404 patients were included. Overall, 63.9% of MIs were ST-elevation MI. Almost all patients in the isolated CAE group had multivessel diffuse ectasia, with 71.3% classified as Markis I, and 26.7% as Markis II. Death or MI recurrence occurred in 54 (26.7%) patients in the isolated CAE group and 33 (16.3%) patients in the control group ( P =0.011). Death occurred in 8 (4.0%) patients in the isolated CAE group versus 6 (3.0%) patients in the control group; recurrent MI in 46 (22.8%) versus 27 (13.4%) patients, respectively. Stent thrombosis was more common in the CAE group compared with the control group (8.9% versus 1.5%; P P =0.017), and recurrent MI (hazard ratio, 2.07 [95% CI, 1.08–3.96]; P =0.029). CONCLUSIONS: The patients with MI due to isolated CAE had a higher risk of recurrent MI and stent thrombosis compared with the patients without CAE. In this study, the rate of recurrent MI from the index infarct artery was also higher in the patients with CAE.
- 1 January 2026
- Published by Kare Publishing in The Anatolian Journal of Cardiology
Seven-Year Clinical and Durability Outcomes of Balloon-Expandable Transcatheter Aortic Valve Implantation in a Turkish Single-Center Cohort
Background: Long-term durability data for early-generation balloon-expandable transcatheter aortic valve implantation (TAVI) in Turkish populations remain limited. The authors evaluated 7-year clinical outcomes and valve durability according to the Valve Academic Research Consortium (VARC-3) criteria. Methods: In this single-center registry, 270 consecutive patients with symptomatic severe aortic stenosis treated with the early-generation balloon-expandable SAPIEN XT valve (January 2012-March 2017) were included. Clinical and echocardiographic outcomes were assessed up to 7 years. The primary endpoint was all-cause mortality. Structural valve deterioration (SVD) and bioprosthetic valve failure (BVF) were defined according to the VARC-3 criteria. Cumulative incidence was estimated using competing-risk analysis, with death from any cause treated as a competing event. Predictors of mortality were evaluated using Cox regression. Results: At 7 years, cumulative survival was 29.6%. Cardiovascular and non-cardiovascular mortality occurred at comparable rates. In multivariable analysis, higher Katz index, reflecting better functional status, and higher body mass index were inversely associated with all-cause mortality, whereas eGFR
- 1 January 2026
- Published by Kare Publishing in The Anatolian Journal of Cardiology
Seven-Year Clinical and Durability Outcomes of Balloon-Expandable Transcatheter Aortic Valve Implantation in a Turkish Single-Center Cohort
Background: Long-term durability data for early-generation balloon-expandable transcatheter aortic valve implantation (TAVI) in Turkish populations remain limited. The authors evaluated 7-year clinical outcomes and valve durability according to the Valve Academic Research Consortium (VARC-3) criteria. Methods: In this single-center registry, 270 consecutive patients with symptomatic severe aortic stenosis treated with the early-generation balloon-expandable SAPIEN XT valve (January 2012-March 2017) were included. Clinical and echocardiographic outcomes were assessed up to 7 years. The primary endpoint was all-cause mortality. Structural valve deterioration (SVD) and bioprosthetic valve failure (BVF) were defined according to the VARC-3 criteria. Cumulative incidence was estimated using competing-risk analysis, with death from any cause treated as a competing event. Predictors of mortality were evaluated using Cox regression. Results: At 7 years, cumulative survival was 29.6%. Cardiovascular and non-cardiovascular mortality occurred at comparable rates. In multivariable analysis, higher Katz index, reflecting better functional status, and higher body mass index were inversely associated with all-cause mortality, whereas eGFR
- Open Access
- 1 August 2025
- Published by Kosuyolu Heart Journal, Health Sciences University in Kosuyolu Heart Journal
- Vol. 28 (2) , 60-65
Relationship Between the Presystolic Wave and the Electrocardiographic Diastolic Index in Hypertensive Patients
Objectives: To examine the association between the presystolic wave (PSW), an echocardiographic parameter indicative of diastolic dysfunction (DD), and the electrocardiographic diastolic index (EDI), which is calculated using 12-lead electrocardiography (ECG), in hypertensive cases. Methods: The study included 250 consecutive patients diagnosed with hypertension, evaluated in two groups: According to PSW presence. Statistical analyses were conducted to compare demographic data, laboratory parameters, and 12-lead ECG parameters between the groups with and without PSW. Results: PSW was found to be linked to advanced age (pConclusion: We determined that, in addition to the echocardiographic assessment of PSW, EDI, an index that can be easily calculated using a 12-lead ECG, may also be a useful parameter for evaluating DD in hypertensive patients.
- 1 August 2025
- Published by Kosuyolu Heart Journal, Health Sciences University in Kosuyolu Heart Journal
- Vol. 28 (2) , 60-65
Open AccessRelationship Between the Presystolic Wave and the Electrocardiographic Diastolic Index in Hypertensive Patients
Objectives: To examine the association between the presystolic wave (PSW), an echocardiographic parameter indicative of diastolic dysfunction (DD), and the electrocardiographic diastolic index (EDI), which is calculated using 12-lead electrocardiography (ECG), in hypertensive cases. Methods: The study included 250 consecutive patients diagnosed with hypertension, evaluated in two groups: According to PSW presence. Statistical analyses were conducted to compare demographic data, laboratory parameters, and 12-lead ECG parameters between the groups with and without PSW. Results: PSW was found to be linked to advanced age (pConclusion: We determined that, in addition to the echocardiographic assessment of PSW, EDI, an index that can be easily calculated using a 12-lead ECG, may also be a useful parameter for evaluating DD in hypertensive patients.
- 30 March 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 19 (9) , 305-316
Predictive power of ALBI score-based nomogram for 30-day mortality following transcatheter aortic valve implantation
This retrospective, multi-center study evaluates the relationships between novel liver function scoring systems - Albumin-Bilirubin (ALBI) score, EZ-ALBI, PALBI, and MELD-XI - and outcomes in patients undergoing transcatheter aortic valve implantation (TAVI). Feature importance was assessed with SHAP-values via the XGBoost-algorithm. The ALBI score exhibited the strongest association with 30-day mortality after TAVI (AUC = 0.723, p < 0.001), outperforming other scores in this regard and consistently demonstrating predictive power across various subgroup populations. Higher 30-day mortality rates were observed in the higher tertiles of the ALBI score compared to the lower tertiles (log-rank p-value = 0.004). The ALBI-based nomogram (C-index = 0.81, 95% CI:0.73-0.86, p = 0 < 001) demonstrated superior predictive power for 30-day mortality post-TAVI compared to the STS (C-index = 0.71, 95% CI :0.64-0.77, p = 0 < 001). In addition, the nomogram showed a significant improvement in reclassification (69.3%, p < 0.001) and a stronger discrimination 15.2%, p < 0.001) compared to the STS. It integrates nine variables, first ALBI score (SHAP:1.165), including NYHA class (0.594), body mass index (0.510), glomerular filtration rate, creatinine, hemoglobin, gender, predilatation requirement, presence of chronic kidney disease, and providing a comprehensive risk assessment tool. This study exhibits the significance of liver dysfunction with AS patients and suggests incorporating liver function parameters in pre-operative risk assessments for better clinical outcomes in TAVI procedures.
- 30 March 2025
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 19 (9) , 305-316
Predictive power of ALBI score-based nomogram for 30-day mortality following transcatheter aortic valve implantation
This retrospective, multi-center study evaluates the relationships between novel liver function scoring systems - Albumin-Bilirubin (ALBI) score, EZ-ALBI, PALBI, and MELD-XI - and outcomes in patients undergoing transcatheter aortic valve implantation (TAVI). Feature importance was assessed with SHAP-values via the XGBoost-algorithm. The ALBI score exhibited the strongest association with 30-day mortality after TAVI (AUC = 0.723, p < 0.001), outperforming other scores in this regard and consistently demonstrating predictive power across various subgroup populations. Higher 30-day mortality rates were observed in the higher tertiles of the ALBI score compared to the lower tertiles (log-rank p-value = 0.004). The ALBI-based nomogram (C-index = 0.81, 95% CI:0.73-0.86, p = 0 < 001) demonstrated superior predictive power for 30-day mortality post-TAVI compared to the STS (C-index = 0.71, 95% CI :0.64-0.77, p = 0 < 001). In addition, the nomogram showed a significant improvement in reclassification (69.3%, p < 0.001) and a stronger discrimination 15.2%, p < 0.001) compared to the STS. It integrates nine variables, first ALBI score (SHAP:1.165), including NYHA class (0.594), body mass index (0.510), glomerular filtration rate, creatinine, hemoglobin, gender, predilatation requirement, presence of chronic kidney disease, and providing a comprehensive risk assessment tool. This study exhibits the significance of liver dysfunction with AS patients and suggests incorporating liver function parameters in pre-operative risk assessments for better clinical outcomes in TAVI procedures.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (4) , e20241621
Relationship between endocardial R-wave amplitude at the apical lead location and regional right ventricular strain analysis
OBJECTIVE: Cardiac implantable electronic devices are widely used today. Therefore, research is ongoing to provide better device implantation in technical terms. The aim of this study was to investigate the relationship between pre-procedural regional right ventricular strain and post-procedural endocardial R-wave amplitude in patients scheduled to receive an implantable cardiac defibrillator.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (4) , e20241621
Open AccessRelationship between endocardial R-wave amplitude at the apical lead location and regional right ventricular strain analysis
OBJECTIVE: Cardiac implantable electronic devices are widely used today. Therefore, research is ongoing to provide better device implantation in technical terms. The aim of this study was to investigate the relationship between pre-procedural regional right ventricular strain and post-procedural endocardial R-wave amplitude in patients scheduled to receive an implantable cardiac defibrillator.
- Open Access
- 1 January 2025
- Published by Sakarya Tip Dergisi in Sakarya Medical Journal
- Vol. 15 (1) , 30-39
The Predictive Role of StrainParameters in Predicting All-Cause Mortality in Diabetic Hypertensive Patients with Normal Left Ventricular Systolic Function in Long-Term Follow-up
Objective: To demonstrate the relationship of all-cause mortality in the long term and speckle-tracking echocardiography parameters in a cohort of diabetic hypertensive cases that had preserved left ventricle ejection fraction (LV-EF). Methods: The study included 141 diabetic hypertensive cases with preserved LV-EF were retrospectively analyzed. After applying exclusion criteria, 121 patients were included. Two groups were formed according to out-of-hospital mortality status. Laboratory and echocardiography data were analyzed. Results: The mean age of the 121 patients was 58.48.04 years, and the median follow-up duration was 10.08 years. Echocardiographic left atrial strain parameters, namely left atrium reservoir phase strain (35.7±8.7 vs 29.8±7.3, p-value: 0.047), left atrium conduit phase strain (LAScd%) (17.6±5.8 vs 13.3±4.1, p-value: 0.028), and left atrium reservoir phase peak strain (1.5±0.4 vs 1.22±0.3, p-value: 0.037), were worse in the mortality group. In right ventricular strain evaluation, four-chamber right ventricular strain (RV4CSL%) (26.1±5.4 vs. 20.8±6.2, p-value: 0.005) was also worse in the mortality group. Multivariate analysis revealed that the mean daytime systolic blood pressure (odds ratio [OR]: 1.769, p-value: 0.028), LAScd% (OR: 0.820, p-value: 0.015), RV4CSL% (OR: 0.078, p-value: 0.043) independently predicted mortality. Kaplan-Meier analysis showed that LAScd%≤15.3 and RV4CSL%≤24.8 were predictive of mortality (p-values: 0.023 and 0.016, respectively). Conclusion: Strain parameters, assessed via echocardiography, can be useful diagnostic and follow-up tools for determining prognosis and guiding early risk factor management in diabetic hypertensive patients, especially in comparison to traditional volumetric parameters.
- 1 January 2025
- Published by Sakarya Tip Dergisi in Sakarya Medical Journal
- Vol. 15 (1) , 30-39
Open AccessThe Predictive Role of StrainParameters in Predicting All-Cause Mortality in Diabetic Hypertensive Patients with Normal Left Ventricular Systolic Function in Long-Term Follow-up
Objective: To demonstrate the relationship of all-cause mortality in the long term and speckle-tracking echocardiography parameters in a cohort of diabetic hypertensive cases that had preserved left ventricle ejection fraction (LV-EF). Methods: The study included 141 diabetic hypertensive cases with preserved LV-EF were retrospectively analyzed. After applying exclusion criteria, 121 patients were included. Two groups were formed according to out-of-hospital mortality status. Laboratory and echocardiography data were analyzed. Results: The mean age of the 121 patients was 58.48.04 years, and the median follow-up duration was 10.08 years. Echocardiographic left atrial strain parameters, namely left atrium reservoir phase strain (35.7±8.7 vs 29.8±7.3, p-value: 0.047), left atrium conduit phase strain (LAScd%) (17.6±5.8 vs 13.3±4.1, p-value: 0.028), and left atrium reservoir phase peak strain (1.5±0.4 vs 1.22±0.3, p-value: 0.037), were worse in the mortality group. In right ventricular strain evaluation, four-chamber right ventricular strain (RV4CSL%) (26.1±5.4 vs. 20.8±6.2, p-value: 0.005) was also worse in the mortality group. Multivariate analysis revealed that the mean daytime systolic blood pressure (odds ratio [OR]: 1.769, p-value: 0.028), LAScd% (OR: 0.820, p-value: 0.015), RV4CSL% (OR: 0.078, p-value: 0.043) independently predicted mortality. Kaplan-Meier analysis showed that LAScd%≤15.3 and RV4CSL%≤24.8 were predictive of mortality (p-values: 0.023 and 0.016, respectively). Conclusion: Strain parameters, assessed via echocardiography, can be useful diagnostic and follow-up tools for determining prognosis and guiding early risk factor management in diabetic hypertensive patients, especially in comparison to traditional volumetric parameters.
- Open Access
- 4 March 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (2) , 410-419
Clinical outcomes of the Myval transcatheter heart valve system in patients with severe aortic valve stenosis: a two-year follow-up observational study
Introduction: Limited data exist on long-term follow-up of severe aortic stenosis (SAS) patients who have undergone transcatheter aortic valve implantation (TAVI) with a new generation, balloon expandable Myval transcatheter heart valve (THV). Thus, we sought to investigate the performance and 2-year clinical outcome of the Myval THV system based on Valve Academic Research Consortium-3 (VARC-3) criteria.Material and methods: A multi-centre, registry-based, observational study was conducted, which included 207 consecutive degenerative SAS patients, from Turkey (n = 128), Italy (n = 58), and Greece (n = 21) (mean [standard deviation] 81 (7) years, 94 [45%] men; 73% NYHA III or IV; EuroSCORE II 5.2% [2.4%]); all patients underwent TAVI with Myval. Patients were followed up at 1 year and 2 years after implantation. Clinical and procedural outcomes were defined according to VARC-3 criteria.Results: Technical success was observed in 204 (99%), device success was observed in 189 (91%), early safety was observed in 161 (78%), and clinical efficacy was observed in 163 (79%) patients. The 30-day death rate was 7.7%; of these, 3.4% were due to cardiovascular reasons. All-cause and cardiovascular mortality rates were 9.7% and 4.3% at 1-year follow-up, and 17.4% and 9.7% at 2-year follow-up, respectively. Incidence of ≥ moderate paravalvular leak (PVL) at 30 days, 1 year and 2 years of follow-up were 3.4%, 4.3% and 4.8%. A total of 11.1% of patients required a permanent pacemaker implantation (PPI) at 30 days after implantation, while the cumulative rate of PPI at 2 years was 12.1%.Conclusions: In this cohort of patients with SAS, the Myval was found to be safe and effective in up to 2 years of follow-up.
- 4 March 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (2) , 410-419
Open AccessClinical outcomes of the Myval transcatheter heart valve system in patients with severe aortic valve stenosis: a two-year follow-up observational study
Introduction: Limited data exist on long-term follow-up of severe aortic stenosis (SAS) patients who have undergone transcatheter aortic valve implantation (TAVI) with a new generation, balloon expandable Myval transcatheter heart valve (THV). Thus, we sought to investigate the performance and 2-year clinical outcome of the Myval THV system based on Valve Academic Research Consortium-3 (VARC-3) criteria.Material and methods: A multi-centre, registry-based, observational study was conducted, which included 207 consecutive degenerative SAS patients, from Turkey (n = 128), Italy (n = 58), and Greece (n = 21) (mean [standard deviation] 81 (7) years, 94 [45%] men; 73% NYHA III or IV; EuroSCORE II 5.2% [2.4%]); all patients underwent TAVI with Myval. Patients were followed up at 1 year and 2 years after implantation. Clinical and procedural outcomes were defined according to VARC-3 criteria.Results: Technical success was observed in 204 (99%), device success was observed in 189 (91%), early safety was observed in 161 (78%), and clinical efficacy was observed in 163 (79%) patients. The 30-day death rate was 7.7%; of these, 3.4% were due to cardiovascular reasons. All-cause and cardiovascular mortality rates were 9.7% and 4.3% at 1-year follow-up, and 17.4% and 9.7% at 2-year follow-up, respectively. Incidence of ≥ moderate paravalvular leak (PVL) at 30 days, 1 year and 2 years of follow-up were 3.4%, 4.3% and 4.8%. A total of 11.1% of patients required a permanent pacemaker implantation (PPI) at 30 days after implantation, while the cumulative rate of PPI at 2 years was 12.1%.Conclusions: In this cohort of patients with SAS, the Myval was found to be safe and effective in up to 2 years of follow-up.